6 5 a r t I C l e S Multiple sclerosis (MS) is an autoimmune inflammatory disease in which T cells attack the myelin sheaths of nerves in the CNS, resulting in neuronal dysfunction 1 . In most patients, MS initiates as a relapsingremitting neurological disorder that over time advances to a chronic progressive disease characterized by the accumulation of neurological deficits. Although MS has long been considered an inflammatory neurodegenerative disease, its etiology is not well understood 2 . The principal 'outside-in' hypothesis for MS pathogenesis centers on the idea that primary dysregulation of the immune system leads to autoreactivity against myelin-sheath components 3,4 , which secondarily leads to breakdown of the blood-brain barrier. This is followed by infiltration of the CNS by T cells, leading to the focal inflammation and demyelination that characterize MS lesions 3 .
a r t I C l e S dead 52 weeks after injection, whereas control littermate (ROSA26-eGFP-DTA) mice developed no symptoms.
Histological analysis of CNS pathology 40 weeks after injection revealed the presence of focal lesions in the brainstem, cerebellum and cervical spinal cord of the tamoxifen-treated DTA mice. These white matter lesions were identified by their lighter staining on sections stained with hematoxylin and eosin (Fig. 2a) . Toluidine blue staining and electron microscopy (EM) analyses of the focal lesions showed the presence of macrophages containing myelin debris (Fig. 2b,c ) and unmyelinated axons (Fig. 2c) , indicating ongoing demyelination. The focal lesions were negative for myelin basic protein (MBP) staining ( Fig. 2d ) and appeared to be sites of active inflammation: they were frequently infiltrated by T cells (Fig. 2d) , and they contained a high density of microglia or macrophages ( Fig. 2d) and, in the cerebellum, unmyelinated axons (Fig. 2d) . Quantitative analysis showed that the focal lesions were rare in the DTA mice 40 weeks after injection: we found on average 2 ± 1 lesions in the cerebellar white matter, 2 ± 2 lesions in the cervical spinal cord white matter and 3 ± 1 lesions in the brainstem white matter by examining hematoxylin and eosin-stained brain sections (~20 sagittal, 10 µm thick) and cervical spinal cord sections (~20 horizontal, 10 µm thick) from these mice (n = 3 mice). No focal white matter lesions were observed in the CNS of control littermate (ROSA26-eGFP-DTA) mice or untreated DTA mice (data not shown). At 1 year after injection, focal lesions were no longer detected in the cerebellum, corpus callosum, cervical spinal cord or brainstem of the tamoxifen-treated DTA mice. These animals did, however, display widespread myelin loss on toluidine blue-stained sections (Fig. 3a) and by EM analysis (Fig. 3b) . Late-onset demyelination in these animals was not associated with substantial loss of oligodendrocytes or neurons in any CNS areas except the brainstem, which showed an approximate 50% decrease in cells stained for the oligodendrocyte marker CC-1 (Fig. 3c) . Quantification of the neuronal biomarker NeuN revealed that there were normal numbers of neurons in the brainstem and the cervical spinal cord (data not shown). Nevertheless, late-onset demyelination significantly affected axonal survival in the DTA animals: counts showed significant axonal loss in the ventrolateral white matter of the cervical spinal cord (~40%) and the optic nerve (~55%) (Fig. 3d) . A similar diminution in axon numbers was not observed in the tamoxifen-treated DTA mice following recovery from the acute demyelinating disease 8 .
Although our previous data showed that the adaptive immune system was not activated at the peak of oligodendrocyte loss (5 weeks after injection) in tamoxifen-treated DTA mice 8 , the late-onset demyelination in these animals was associated with T cell inflammation in the CNS. Staining for the T cell marker CD3 showed increased numbers of CD3 + T cells 53 weeks after injection in the tamoxifen-treated DTA mice (Supplementary Fig. 1 ). Notably, similar analyses also showed increased numbers of CD3 + T cells in the CNS of tamoxifentreated DTA mice as early as 7 weeks after injection (data not shown), when the mice had started recovering from the initial oligodendrocyte loss. Flow cytometry 10 and 40 weeks after injection revealed that the number of CD4 + T cells present in the CNS of tamoxifentreated DTA mice was significantly higher than that in control littermates (ROSA26-eGFP-DTA) (Fig. 4a,b) . Additionally, at 40 weeks after injection, the number of MHCII + B7 + (CD80 + CD86 + ) dendritic cells was significantly higher in tamoxifen-treated DTA mice than in control mice (Fig. 4b) . Dendritic cells represent the main CNS antigen-presenting cell type during CD4 + T cell-induced inflammatory demyelinating response in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE) 11 . Therefore, activated CD4 + T cells are present in the CNS as early as 10 weeks after injection, and both activated CD4 + T cells and antigen-presenting dendritic cells are present in the CNS 40 weeks after injection.
Flow cytometry analysis 40 weeks after injection, to investigate whether myelin-specific CD4 + T cell responses were quantifiable in Control mice: 19-32 weeks, n = 5; 33 and 46-51 weeks, n = 9; 34, 35 and 43-45 weeks, n = 11; 36, 41 and 42 weeks, n = 14; 37-40 weeks, n = 15; 52 weeks, n = 7. DTA mice: 19-32 weeks, n = 4; 33 and 42 weeks, n = 10; 34 weeks, n = 12; 35 and 41 weeks, n = 11; 36-39 weeks, n = 15; 40 weeks, n = 14; 43 weeks, n = 9; 44 weeks, n = 7; 45-50 weeks, n = 5; 51-52 weeks, n = 3. Significance between control and DTA mice: 38 weeks, P = 0.0005; 39 weeks, P = 0.0094; 40 weeks, P = 0.0024; 41 weeks, P = 0.0002; 42 weeks, P = 0.0025; 43 weeks, P = 0.0207; 52 weeks, P = 0.0095. (b) Concurrently with the late-onset disease, the tamoxifen-treated DTA mice showed significant weight loss as compared to control littermate mice. Control mice: 32 weeks, n = 5; 33 weeks, n = 10; 34-35 and 43-45 weeks, n = 11; 36, 41 and 42 weeks, n = 14; 37-40 weeks, n = 15; 46-51 weeks, n = 9; 52 weeks, n = 7. DTA mice: 32 weeks, n = 4; 33-34 weeks, n = 10; 35 and 41 weeks, n = 12; 36-39 weeks, n = 16; 40 weeks, n = 15; 42 weeks, n = 11; 43 weeks, n = 9; 44 weeks, n = 8; 45-49 weeks, n = 6; 50-52 weeks, n = 5. Significance between control and DTA mice: 37 weeks, P = 0.021; 50 weeks, P = 0.0063; 51 weeks, P = 0.0063; 52 weeks, P = 0.0188. Data in a and b are presented as the mean ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001; two-way ANOVA with Bonferroni post hoc analysis. npg a r t I C l e S the spleens and cervical lymph nodes of tamoxifen-treated DTA mice, indicated that there was no statistical difference in the number of CD4 + T cells, CD8 + T cells, B cells, monocytes and dendritic cells present in the spleen of tamoxifen-treated DTA mice compared with controls (Fig. 4c) . The total numbers of CD4 + T cells, CD8 + T cells, B cells, monocytes and dendritic cells in the CNS-draining cervical lymph nodes of tamoxifen-treated DTA mice were significantly higher than in those of the controls (Fig. 4d) . In contrast to findings 10 weeks after injection (data not shown), at 40 weeks after injection autoreactive T cells capable of proliferating in response to stimulation with recombinant rat MOG protein were seen in the spleen and cervical lymph nodes, and autoreactive T cells capable of proliferating in response to stimulation with the immunodominant MOG epitope were found in the spleen (Fig. 4e,f Figure 2 Focal white matter lesions at early disease stages. (a) Focal white matter lesions (arrows) were detected in different CNS areas of the tamoxifen-treated Plp1-CreER T ;ROSA26-eGFP-DTA mice ~40 weeks after injection, such as the brainstem white matter, the cerebellar white matter and the cervical spinal cord white matter. They appear as lighter areas on sections stained with hematoxylin and eosin. Insets show higher magnifications of lesions. Scale bars: 50 µm (brainstem) and 100 µm (cervical cord, cerebellum). (b,c) A focal lesion is outlined in the cerebellar white matter (dashed lines) on a toluidine blue-stained section (b). The lesion contains a high density of macrophages with lipids from degrading myelin (arrow) and myelin debris (arrowhead) in their cytoplasm, which are also shown at higher resolution by EM (c, left). A higher magnification EM image of the myelin debris is shown in c, right. EM analysis also demonstrates the presence of unmyelinated axons (ax) in the focal lesions (c, left panel). Scale bars: 10 µm (b), 2 µm (c, left) and 200 nm (c, right). (d) Focal lesions showed loss of MBP staining in the cerebellar white matter and the cervical spinal cord white matter (green, arrows), and they frequently contained T cells stained for CD3 (gray). These sites also showed increased staining for the microglia and macrophage marker CD11b (red in cervical cord, gray in cerebellum). A few unmyelinated axons were also detected in the white matter lesions by SMI31 staining (red in cerebellum, arrows). Immunofluorescence images are representative of three mice per genotype. Scale bars, 50 µm. npg a r t I C l e S mice appeared to be below the level of functional detection owing to low precursor frequency in the absence of a strong stimulus such as priming with MOG emulsified in complete Freund's adjuvant, we tested the activation and the proliferation of carboxyfluorescein succinimidyl ester (CFSE)-labeled naive MOG 35-55 -specific T cell antigen receptor (TCR) transgenic T cells (2D2) 12 in the CNS and spleen 1 week after transfer into tamoxifen-treated DTA and control littermate (ROSA26-eGFP-DTA) recipient mice. The CFSE-labeled 2D2 CD4 + T cells showed increased proliferation and production of proinflammatory cytokines interferon (IFN-γ) and interleukin (IL)-17 in both the CNS (Fig. 5a,b ) and the spleens (Fig. 5c ) of the tamoxifen-treated DTA mice. In addition, splenocytes collected from the tamoxifen-treated DTA mice showed increased proliferation and higher levels of the secreted proinflammatory T H 1 and T H 17 cytokines IFN-γ, granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-17 upon ex vivo restimulation in the presence of MOG peptide ( Fig. 5d-g ). These data indicate that activated MOG 35-55 -specific T cells are present early in the CNS and spleens of the tamoxifen-treated DTA mice, raising the possibility that the CNS might be the primary initiation site of the autoimmune response against myelin observed in these animals later in life. This is the same anatomical location in which CD4 + T cells expressing a TCR specific for another myelin peptide beside the disease-inducing myelin peptide (that is, spread epitope-specific CD4 + T cells) are activated during relapsing-remitting EAE in SJL mice 13 . We also explored the possibility that the late-onset demyelination found in the CNS of tamoxifen-treated DTA mice was caused by oligodendrocyte loss due to tamoxifen-independent CreER T -mediated recombination of the ROSA26-eGPF-DTA allele. This possibility was raised by our finding that modest levels of gene recombination occurred in the absence of tamoxifen treatment in Plp1-CreER T ;ROSA26-EYFP reporter mice. Expression of the reporter protein YFP occurred in a small percentage of oligodendrocytes staining positive for CC-1 in all CNS areas of the untreated Plp1-CreER T ;ROSA26-EYFP (reporter) mice at 52 weeks ( Supplementary Fig. 2a ). Therefore, we tested whether tamoxifen-independent recombination occurred in , total CD8 + T cells (total CD3 + CD4 − CD8 + ) (in cervical lymph nodes, P = 0.0001), B cells (CD3 − CD19 + ) (in cervical lymph nodes, P = 0.0004), monocytes (CD3 − CD11b + CD11c − ) (in cervical lymph nodes P = 0.0100) and dendritic cells (CD3 − CD11b − CD11c + ) (in cervical lymph nodes P = 0.0267) were determined by flow cytometry in the spleens (c) and cervical lymph nodes (d) of tamoxifen-treated DTA mice 40 weeks after injection and control mice. Additionally, splenocytes (e) and cervical lymph node cells (f) (1 × 10 6 per well) were activated in culture for 72 h in the presence of medium alone or with anti-CD3 (1 µg/ml) (spleen, P = 0.0118; cervical lymph node, P = 0.012), OVA 323-339 , PLP 139-151 , PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] , MBP 84-104 or MOG (spleen, P < 0.0001) or whole recombinant rat MOG (rMOG) protein (10 µg/ml) (spleen, P < 0.0001; cervical lymph node, P = 0.0005), with pulsed tritiated thymidine (1 µCi) added at 24 h. The levels of cellular proliferation were then determined. One representative experiment of three is presented. Three mice from each group were assessed per experiment. The data are presented as the mean + s.e.m. Counts per minute (CPM) of triplicate cultures. *P < 0.05, **P < 0.01 and ***P < 0.001 for differences between control mice and tamoxifen-treated DTA mice; two-way ANOVA with Bonferroni post hoc analysis. npg a r t I C l e S various CNS regions of the untreated reporter mice at younger ages.
We found very few to no CC-1 and YFP double-positive cells at 13 weeks of age, whereas these cells were more numerous by 26 weeks of age. Likewise, there appeared to be a further increase in the number of CC-1 and YFP double-positive cells present in various CNS regions of untreated reporter mice with age, thereby showing a trend toward increased numbers of oligodendrocytes expressing YFP in most of these areas at 52 weeks (6-20%) compared to 26 weeks (6-14%) (Supplementary Fig. 2b) .
Since a modest level of gene recombination appeared in the absence of tamoxifen treatment in the untreated reporter mice, we determined whether any neurological symptoms and myelin loss were present in untreated DTA mice as they aged. Although the untreated DTA mice appeared phenotypically normal up to 60 weeks of age (Supplementary Movie 2), they did show some myelin loss in most CNS areas at the age of 52 weeks via EM analysis (Supplementary Fig. 3a) . Nevertheless, these mice did not display motor defects on the rotarod (Supplementary Fig. 4a ) or substantial weight loss (Supplementary Fig. 4b ) at time points when the tamoxifen-treated DTA mice were severely impaired. Moreover, these animals showed much less demyelination than the tamoxifen-treated DTA mice at 53 weeks after injection (Supplementary Fig. 3a ). This finding was further supported by morphometric analysis of the corpus callosum, which showed that untreated DTA mice had ~30% fewer unmyelinated axons than tamoxifen-treated DTA mice (Supplementary Fig. 3b ). In addition, tissue sections from both groups of mice showed myelinated axons with increased g-ratios, indicating thinner myelin, as compared to control (ROSA26-eGFP-DTA) mice (Supplementary Fig. 3c ).
In contrast to that in the tamoxifen-treated DTA mice, CNS demyelination in untreated DTA mice was not associated with CD3 + T cell inflammation (Supplementary Fig. 5a ) nor development of peripheral CD4 + T cell responses to MOG in lymphoid organs ( Supplementary  Fig. 5b) . Furthermore, flow cytometric analysis of the CNS tissues and peripheral lymphoid organs showed equivalent numbers of various immune cell populations present in the spleen ( Supplementary  Fig. 5c ), cervical lymph nodes (Supplementary Fig. 5d ) and CNS (Supplementary Fig. 5e ). Therefore, the late-stage demyelination in tamoxifen-treated DTA mice is specifically associated with CNS infiltration of activated CD4 + T cells and dendritic cells, as well as with the presence of peripheral MOG-specific autoreactive CD4 + T cells.
Adoptive transfer of DTA-derived MOG-specific T cells elicits CNS inflammation
Our finding of MOG-specific CD4 + T cell responses in tamoxifentreated DTA mice 40 weeks after injection raised the possibility that the late-onset demyelinating disease observed in these mice might be T cell mediated. To examine this possibility, we crossed the DTA model onto a Rag1 −/− background 14 : Rag1 −/− mice do not produce mature B or T cells. However, this approach was not successful because the tamoxifen-treated Rag1-deficient DTA mice did not recover from the acute demyelinating disease, indicating that T cells could act beneficially in CNS repair, as previously suggested [15] [16] [17] . Furthermore, we were not able to block T cells from entering the CNS 18 of the tamoxifen-treated DTA mice by repeated long-term injections of an anti-α4-integrin (VLA-4) rat monoclonal antibody (data not shown). The long-term exposure of these animals may have resulted in an immune response against the injected antibody. In line As an alternative approach, we determined the encephalitogenic potential of MOG -specific CD4 + T cells in tamoxifen-treated DTA mice during the late-onset disease. Splenocytes were collected and cultured from these mice 40-52 weeks after injection or , blast cells (9.3 ± 1.56%) were present in the cultures from tamoxifen-treated DTA mice, whereas numbers of blast cells in cultures from control mice were negligible. The recipient mice were followed for disease, and the Rag1 −/− mice that received MOG -activated DTA mouse cells showed a mild, but consistent and reproducible, EAE-like disease phenotype characterized by hindlimb weakness, mild ataxia and a hunched posture (Fig. 6a) . Unlike with the use of MOG -specific T cells from donors primed with MOG in complete Freund's adjuvant 20 , we were able to transfer disease only to Rag1 −/− mice, not to wild-type C57BL/J mice ( Supplementary Fig. 6a,b) . We consider this disease to be significant (P < 0.001 on days 24-39, two-way ANOVA with Bonferroni post hoc analysis) as we also found that MOG 35-55 -specific TCR transgenic T cells purified from 2D2 mice and activated in T H 1-or T H 17-promoting conditions (Supplementary Fig. 6c) Fig. 6d ). On day 22 after cell transfer, the CNS and spleen were collected from the recipient mice. The number of total cells in the spleen and CNS of the recipients of cells from the tamoxifen-treated donor mice was significantly greater than in the recipients of cells from untreated control littermates (Fig. 6b,c) . Histological analysis of brain and spinal cord sections from Rag1 −/− mice revealed focal areas of T cell infiltration and increased microglia or macrophage activation by CD3 and IBA-1 immunostaining, respectively, which occurred mostly in the white matter-rich areas of the brainstem (Fig. 6d) and the corpus callosum (data not shown) of the mice inoculated with T cells derived from tamoxifen-treated DTA mice. Nevertheless, MBP staining looked normal (Fig. 6d) , indicating that myelin may not be drastically disrupted in these areas, despite the increased inflammation, consistent with the mild disease symptoms observed in the Rag1 −/− mice inoculated with the DTA-derived cells. A distinct adoptive transfer protocol in which fewer T cells (2 × 10 6 ) were transferred resulted in a milder neurological phenotype in the Rag1 −/− recipients (data not shown). CNS samples from these animals were examined 42 d after transfer. EM analysis of brain and lower lumbar spinal cord from the recipient mice showed scattered focal areas of demyelination in the white matter of the cerebella and lower lumbar spinal cords of only mice inoculated with T cells derived from tamoxifen-treated DTA mice (Supplementary Fig. 7a ). In these mice, the number of myelinated axons was reduced by around 30% compared to that in mice inoculated with T cells from control mice (Supplementary Fig. 7b) .
The above findings suggest that DTA-derived MOG 35-55 activated splenic CD4 + T cells are able to enter the CNS and induce a mild demyelinating disease following adoptive transfer into Rag1 −/− recipient mice. Therefore, we tested whether MOG 35-55 -specific immune tolerance using the intravenous (i.v.) infusion of MOG -coupled poly(lactic-co-glycolic acid) (PLG) nanoparticles 21 could inhibit the ability of DTA-derived MOG activated splenic CD4 + T cells to induce disease in Rag1 −/− recipient mice. The treatment of DTAderived cell recipient mice with MOG 35-55 -coupled PLG nanoparticles on the day of MOG blast cell transfer significantly inhibited disease severity as compared to that in DTA-derived cell recipient were assessed by culturing 1 × 10 6 total splenocytes for 3 d with medium alone, anti-CD3 (1 µg/ml), OVA 323-339 , MOG or PLP 178-191 (10 µg/ml). The levels of secreted IFN-γ (e) (MOG activation P < 0.0001), IL-17 (f) and cellular proliferation (g) (MOG activation P < 0.0001) as determined by tritiated thymidine incorporation were assessed. One representative experiment of two is presented with n = 6 mice per group. The data are presented as the mean + s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 for differences shown between the different groups. Two-way ANOVA with Bonferroni post hoc analysis. npg a r t I C l e S mice treated with OVA 323-339 -coupled PLG particles (Fig. 7a) (Fig. 7b,c and Supplementary Fig. 8a-c) . In contrast, there was a significantly higher number of total CD4 + T cells in the spleen of the MOG 35-55 -PLG-treated DTA-derived cell recipient mice, as compared to that in OVA 323-339 -PLG treated DTA-derived cell recipient mice, but no statistical difference in the number of IFN-γ + CD4 + , IL-17 + CD4 + , and Ki67 + CD4 + T cells between the MOG 35-55 -PLG-and OVA 323-339 -PLG-treated DTA-derived cell recipient mice (Fig. 7d,e and Supplementary Fig. 8d-f (Fig. 8a ) and weight loss (Fig. 8b) . MOG -specific tolerance also decreased CD4 + T cell infiltration, proliferation and production of the proinflammatory cytokine IFN-γ in the CNS ( Fig. 8c and Supplementary Fig. 9a-g ), but not the spleens of the DTA mice ( Fig. 8d and Supplementary Fig. 9h-m) . When isolated splenocytes from the MOG 35-55 -tolerized tamoxifen-treated DTA mice were cultured in vitro in the presence of the MOG 35-55 peptide, they secreted lower levels of the proinflammatory cytokine IFN-γ (Fig. 8e) , did not produce appreciable amounts of IL-17 ( Fig. 8f) , and showed decreased proliferation (Fig. 8g) , consistent with the expected tolerance to the MOG peptide. Overall, the data strongly favor the conclusion that the late-onset disease in tamoxifen-treated DTA mice is mediated by activated CD4 + MOG-specific T cells, which arise as a result of the oligodendrocyte ablation in early life.
DISCUSSION
The evidence presented here strongly suggests that induction of extensive oligodendrocyte loss in young adult DTA mice is sufficient to activate CD4 + T cell-mediated immune responses against myelin that lead to a severe, late-onset demyelinating disease. Although oligodendrocyte loss in tamoxifen-treated DTA mice did not activate the adaptive immune system at the peak of acute disease (5 weeks after injection), substantial CNS infiltration of activated CD4 + T cells occurred during the remyelination stages (at 10 weeks after injection). Furthermore, all tamoxifen-treated DTA mice in this study developed a fatal, secondary demyelinating disease starting approximately 40 weeks after injection. At this late-onset disease time point, focal inflammatory demyelinating lesions were found in various white matter-rich CNS areas of the tamoxifen-treated DTA mice. These focal lesions appeared to progress, as extensive myelin loss was observed throughout the CNS 1 year after injection. These late changes were associated with infiltration of activated CD4 + T cells and dendritic cells into the CNS. We also found that MOG 35-55 -specific T cells were present in the peripheral lymphoid organs of tamoxifen-treated DTA mice at the time of CNS infiltration, which indicates an ongoing immune response against myelin during the late-onset disease.
In support of the conclusion that myelin peptide-specific CD4 + T cells become reactivated at later time points after oligodendrocyte ablation, we found activated CD4 + T cells to be already present in the CNS of the tamoxifen-treated DTA mice much earlier as assessed via flow cytometric analysis 10 weeks after injection. Additionally, in cell tracking experiments, a higher number of transferred CFSE-labeled MOG -specific 2D2 CD4 + T cells were present in the CNS of the DTA mice during the recovery period after ablation, and these T cells were more proliferative and a greater number were either IFN-γ + or IL-17 + when compared to those in control littermate recipients. Taken together, these data indicate that the CNS might be the primary initiation site of the autoimmune response against myelin observed in these animals during the late-onset disease.
Like progressive MS 22 , the late-onset demyelinating disease in the tamoxifen-treated DTA mice is also associated with axonal loss in the CNS. Therefore, this mouse model is ideal for studying the mechanisms of neuronal degeneration in adult-onset demyelinating diseases like MS, as well as for validating new therapeutic treatments that could promote remyelination and neuroprotection in the CNS.
Late-onset disease was not associated with appreciable oligodendrocyte loss in most areas of the CNS. We did, however, detect a low level of tamoxifen-independent recombination in the CreER T driver line (Plp1-CreER T ) used in the DTA model (Supplementary Fig. 2) . Nevertheless, demyelination in untreated DTA mice was mild and the mice showed no neurological symptoms. Moreover, this tamoxifenindependent demyelination was not associated with myelin-specific T cell responses or inflammation in the CNS. This finding supports the hypothesis that induction of extensive oligodendrocyte loss is required for the activation of the MOG-specific T cell responses detected in tamoxifen-treated DTA mice during the secondary, late-onset demyelinating disease. The association between severe demyelination in tamoxifen-treated DTA mice and the presence of inflammatory CD4 + T cells and dendritic cells in the CNS suggest that the late-onset demyelination is mediated by MOG-specific T cells found in these animals. This possibility is further supported by the proliferative and proinflammatory T H 1 (IFN-γ) and T H 17 (IL-17) responses by MOG -specific CD4 + T cells present in tamoxifentreated DTA mice and by the ability of these cells to consistently induce EAE-like neurological symptoms that correlated with active inflammatory lesions in the CNS white matter when inoculated into naive Rag1 −/− mice. The absence of a B-cell response in the Rag1 −/− recipient mice 14 might explain why more severe clinical symptoms were not observed. Lastly, an autoimmune basis for the late-onset disease in DTA mice is strongly supported by our data showing amelioration of the late-onset disease symptoms in tamoxifen-treated DTA mice that were tolerized specifically to the MOG peptide.
It is intriguing that although autoimmune responses against myelin peptides have been detected in mice after they were administered the demyelinating neurotoxin cuprizone for 4 weeks and switched to normal diet for 2 weeks (ref. 23) , secondary CNS demyelination has not been detected in the cuprizone mouse model after longterm survival 24 . Also, we have not found evidence of late-onset CNS demyelination and T cell infiltration in cuprizone-fed C57BL/6J mice surviving as long as 10 months after recovering from oligodendrocyte loss and demyelination (M.T. and B.P. unpublished data). One possible explanation for these differences is simply that demyelination is more widespread in the DTA model, generating more myelin antigen, than in mice treated with cuprizone, which primarily affects npg a r t I C l e S the corpus callosum and superior cerebellar peduncle 25 . Alternatively, or additionally, cuprizone might have a direct immunosuppressant effect. In support of this possibility, it has also been shown that cuprizone inhibits the development of EAE as well as graft-versus-host disease, and that these effects correlate with alterations to peripheral T cell responses 26 .
Our evidence seems to contradict the study of oligodendrocyte ablation in the oligodendrocyte-expressed diphtheria toxin receptor (oDTR) genetic mouse model, in which oligodendrocyte death does not induce an adaptive immune response against myelin even under conditions that favor autoimmunity 27 . Induction of oligodendrocyte death and CNS demyelination in the oDTR model are achieved by direct administration of diphtheria toxin; this leads to neurodegeneration that results in a severe phenotype and premature death. Therefore, detection of secondary anti-CNS immunity in the oDTR model might be precluded by the early death of the mice. Also, several genetic mouse models of inducible oligodendrocyte death have been described, all of which exhibit severe phenotypes and early death, which precludes the ability to track the mice over an extended time course, as was done in the present model system [28] [29] [30] [31] [32] . Nevertheless, no T cell infiltration of the CNS has been reported in any of these models, which further suggests that long-term survival after oligodendrocyte death is crucial to the development of autoimmunity and late-onset disease in the DTA model. Thus, development of CNS autoimmunity after oligodendrocyte loss could be a slow process. This delay might explain the difficulty in observing a correlation between oligodendrocyte loss, whether induced by viral cytotoxicity or other environmental factors, and a myelin immune response in patients with MS 5 . In line with this idea, it has been shown recently that nascent MS lesions with oligodendrocyte loss, in the absence of the adaptive immune infiltrates, occurred in a patient who tested positive for the Clostridium perfringens type B, indicating that MS might be triggered by an agent cytotoxic to oligodendrocytes 33 . Both type B and D strains of C. perfringens cause a severe demyelinating disease in ruminant animals that is similar to human MS by producing ε-toxin, which specifically targets and kills mature oligodendrocytes in the CNS 34 .
Notably, focal oligodendrocyte death in the CNS induced by lentivirus-mediated expression of caspase 9 leads to the infiltration of CD3 + T cells into demyelinated areas 35 , which is similar to the response in the DTA mouse model, although the presence of myelin-specific immune responses was not investigated in the lentivirus model. Furthermore, T cell infiltration has been detected in the CNS of mice carrying genetic defects that result in oligodendrocyte abnormalities, such as Pex5 conditional knockout mice 36 , Plp1-overexpressing mice 37 , and galactosylceramidase-deficient twitcher mice, a murine model of the severe demyelinating Krabbe disease [38] [39] [40] . Therefore, CNS immune responses secondary to oligodendrocyte abnormalities may be more common than previously appreciated and, as demonstrated by the late-onset DTA model, may be of clinical significance. Nevertheless, several studies have unequivocally shown that MS susceptibility is mostly associated with genes that are linked to the immune system 41, 42 , indicating that a permissive immune system is also required for the primary oligodendrocyte damage to lead to MS pathogenesis.
Overall, our data show that oligodendrocyte death in young animals, which occurs in the absence of blood-brain barrier breakdown 8 , can induce late-onset CNS autoimmunity. This evidence supports the 'inside-out' hypothesis: certain forms of MS may be caused by primary oligodendrocyte loss or myelin damage that secondarily leads to activation of the permissive adaptive immune system and CNS inflammation. Therefore, we believe that the DTA mouse model is uniquely suited to elucidating the initiation of CNS autoimmunity, which is not well understood. This mouse model also offers the opportunity to screen new therapeutic approaches to prevent activation of the adaptive immune system and thereby protect the CNS from immune-mediated inflammatory damage. Moreover, the late-onset DTA disorder, which is characterized by widespread demyelination, axonal loss and persistent clinical deterioration, is reminiscent of the progressive phase of MS, suggesting that the DTA model might provide critical insight into the pathogenesis of late-stage, chronic MS.
METhODS
Methods and any associated references are available in the online version of the paper. 
